A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer

This study is testing a combination of two new drugs — SHR-A2102 (an antibody-drug combination that delivers chemotherapy directly to cancer cells) and adebrelimab (an immunotherapy drug) — for people with advanced or metastatic esophageal squamous cell carcinoma (a type of cancer in the food pipe). The goal is to see if this combination is safe and effective. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with locally advanced or metastatic esophageal squamous cell carcinoma confirmed by biopsy - Your cancer has at least one measurable area on imaging - You are generally in good health and able to carry out daily activities **You may NOT be eligible if...** - Your cancer has spread to the brain in an uncontrolled way - You have had recent major surgery, radiation, or prior cancer treatment within 4 weeks - You have received antibody-drug conjugates with topoisomerase I inhibitors before - You have active Hepatitis B or C, HIV, or active tuberculosis - You have a history of immune deficiency - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.